Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy

Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy

BackgroundPatients with stage II to III breast cancer have a high recurrence rate. The early detection of recurrent breast cancer remains a major unmet need. Circulating tumor DNA (ctDNA) has been proven to be a marker of disease progression in metastatic breast cancer. We aimed to evaluate the prog...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Po-Han Lin, Ming-Yang Wang, Chiao Lo, Li-Wei Tsai, Tzu-Chun Yen, Thomas Yoyan Huang, Wei-Chih Huang, Karen Yang, Chih-Kai Chen, Sheng-Chih Fan, Sung-Hsin Kuo, Chiun-Sheng Huang
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
circulating tumor DNA
neoadjuvant therapy
breast cancer
recurrence
next-generation sequencing
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/5c086e33a22b4ccca39c569b8be44274
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/5c086e33a22b4ccca39c569b8be44274

Ejemplares similares